Clinical Trials
66 trialsSintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Regeneron Pharmaceuticals
KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer
National Cancer Institute, Egypt
WOLF
University of Pittsburgh
STRAP
National Cancer Centre, Singapore
POST-BIO
Gruppo Oncologico del Nord-Ovest
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Daiichi Sankyo
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
Shanghai Miracogen Inc.
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
University of California, San Diego
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
University of Pittsburgh
MK-1454-002
Merck Sharp & Dohme LLC
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
University of California, San Diego
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Sun Yat-sen University
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Shanghai Miracogen Inc.
JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
Shanghai JMT-Bio Inc.
Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC
Sun Yat-sen University
Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC
Sun Yat-sen University
Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)
Sun Yat-sen University
Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC
The University of Hong Kong
FRAIL-IMMUNE
Centre Leon Berard
Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer
Nanfang Hospital, Southern Medical University
V-CHANCE
National Cancer Institute, Naples
Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN
Eye & ENT Hospital of Fudan University
Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma
Nanfang Hospital, Southern Medical University
Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor
Endocyte
OPTIM
AIO-Studien-gGmbH
ELANFIT
Groupe Oncologie Radiotherapie Tete et Cou
A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for Recurrent Head and Neck Cancer.
PCI Biotech AS
Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Novartis
NISCAHN
UNICANCER
Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy
Chinese University of Hong Kong
ORL03
UNICANCER
Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer
Pfizer
Endostar for Locally Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
EXTAX
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
AstraZeneca
Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck
AstraZeneca
Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN
UNC Lineberger Comprehensive Cancer Center
RePASS
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Efficacy of SU 011248 in Head And Neck Carcinoma
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Nedaplatin Combined With Gemcitabine in the Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma : a Single Arm and Phase â…¡ Clinical Trail
Sun Yat-sen University
PIK-ORL
Centre Leon Berard
Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
Celgene
A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
Amgen
Nimotuzumab for Recurrent Nasopharyngeal Carcinoma
Fujian Cancer Hospital
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy
Novartis
Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma
University of Pittsburgh
TPEx
Groupe Oncologie Radiotherapie Tete et Cou